SNDL (SNDL) Competitors $1.86 0.00 (0.00%) Closing price 02/14/2025 04:00 PM EasternExtended Trading$1.86 +0.00 (+0.27%) As of 02/14/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends SNDL vs. IDYA, AGIO, SDGR, APGE, NAMS, BLTE, TVTX, IRON, IOVA, and WVEShould you be buying SNDL stock or one of its competitors? The main competitors of SNDL include IDEAYA Biosciences (IDYA), Agios Pharmaceuticals (AGIO), Schrödinger (SDGR), Apogee Therapeutics (APGE), NewAmsterdam Pharma (NAMS), Belite Bio (BLTE), Travere Therapeutics (TVTX), Disc Medicine (IRON), Iovance Biotherapeutics (IOVA), and Wave Life Sciences (WVE). These companies are all part of the "pharmaceutical products" industry. SNDL vs. IDEAYA Biosciences Agios Pharmaceuticals Schrödinger Apogee Therapeutics NewAmsterdam Pharma Belite Bio Travere Therapeutics Disc Medicine Iovance Biotherapeutics Wave Life Sciences SNDL (NASDAQ:SNDL) and IDEAYA Biosciences (NASDAQ:IDYA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings. Do analysts rate SNDL or IDYA? SNDL currently has a consensus price target of $3.25, indicating a potential upside of 74.73%. IDEAYA Biosciences has a consensus price target of $53.58, indicating a potential upside of 155.16%. Given IDEAYA Biosciences' higher possible upside, analysts plainly believe IDEAYA Biosciences is more favorable than SNDL.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SNDL 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00IDEAYA Biosciences 0 Sell rating(s) 2 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.94 Which has more volatility and risk, SNDL or IDYA? SNDL has a beta of 3.11, suggesting that its stock price is 211% more volatile than the S&P 500. Comparatively, IDEAYA Biosciences has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Does the media favor SNDL or IDYA? In the previous week, IDEAYA Biosciences had 19 more articles in the media than SNDL. MarketBeat recorded 19 mentions for IDEAYA Biosciences and 0 mentions for SNDL. IDEAYA Biosciences' average media sentiment score of 0.30 beat SNDL's score of -0.10 indicating that IDEAYA Biosciences is being referred to more favorably in the news media. Company Overall Sentiment SNDL Neutral IDEAYA Biosciences Neutral Is SNDL or IDYA more profitable? IDEAYA Biosciences has a net margin of 0.00% compared to SNDL's net margin of -12.11%. SNDL's return on equity of -8.27% beat IDEAYA Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets SNDL-12.11% -8.27% -6.96% IDEAYA Biosciences N/A -19.42%-18.63% Do institutionals and insiders believe in SNDL or IDYA? 98.3% of IDEAYA Biosciences shares are held by institutional investors. 3.5% of IDEAYA Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community prefer SNDL or IDYA? IDEAYA Biosciences received 1 more outperform votes than SNDL when rated by MarketBeat users. However, 72.31% of users gave SNDL an outperform vote while only 71.72% of users gave IDEAYA Biosciences an outperform vote. CompanyUnderperformOutperformSNDLOutperform Votes14172.31% Underperform Votes5427.69% IDEAYA BiosciencesOutperform Votes14271.72% Underperform Votes5628.28% Which has higher valuation and earnings, SNDL or IDYA? IDEAYA Biosciences has lower revenue, but higher earnings than SNDL. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than SNDL, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSNDL$673.33M0.73-$127.91M-$0.31-6.00IDEAYA Biosciences$23.39M77.60-$112.96M-$2.33-9.01 SummaryIDEAYA Biosciences beats SNDL on 11 of the 19 factors compared between the two stocks. Get SNDL News Delivered to You Automatically Sign up to receive the latest news and ratings for SNDL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNDL vs. The Competition Export to ExcelMetricSNDLMedicinals & botanicals IndustryMedical SectorNASDAQ ExchangeMarket Cap$488.77M$1.20B$5.76B$9.22BDividend YieldN/AN/A5.27%4.00%P/E Ratio-6.0039.6026.2019.44Price / Sales0.735.72456.5777.34Price / CashN/A10.8846.0638.90Price / Book0.541.917.355.05Net Income-$127.91M-$53.22M$3.19B$222.81M7 Day Performance0.54%2.06%1.69%1.29%1 Month Performance4.49%3.83%4.13%1.52%1 Year Performance24.83%-7.80%22.24%16.53% SNDL Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNDLSNDL3.6134 of 5 stars$1.86flat$3.25+74.7%+24.8%$488.77M$673.33M-6.002,516IDYAIDEAYA Biosciences3.6893 of 5 stars$22.43-2.5%$53.67+139.3%-55.4%$1.94B$23.39M-9.6380Earnings ReportAnalyst ForecastAnalyst RevisionAGIOAgios Pharmaceuticals4.2447 of 5 stars$33.92+1.4%$56.33+66.1%+25.3%$1.92B$26.82M2.97390Earnings ReportAnalyst DowngradeShort Interest ↓SDGRSchrödinger2.1591 of 5 stars$25.24-1.7%$32.11+27.2%-23.5%$1.84B$216.67M-10.78790Positive NewsAPGEApogee Therapeutics2.5885 of 5 stars$39.37-0.9%$89.71+127.9%+1.7%$1.78BN/A-16.3191NAMSNewAmsterdam Pharma3.4162 of 5 stars$19.24-4.7%$41.60+116.3%-3.9%$1.78B$14.09M0.004Positive NewsBLTEBelite Bio3.5122 of 5 stars$53.79-6.5%$96.33+79.1%+17.6%$1.66BN/A-48.5410Short Interest ↓TVTXTravere Therapeutics2.4491 of 5 stars$21.08-3.1%$24.00+13.9%+179.4%$1.64B$145.24M-4.63460IRONDisc Medicine2.0913 of 5 stars$54.40-0.8%$88.90+63.4%-17.9%$1.62BN/A-13.7030Short Interest ↑IOVAIovance Biotherapeutics4.0949 of 5 stars$5.32-6.6%$22.69+326.9%-39.1%$1.62B$90.86M-3.57500WVEWave Life Sciences4.2973 of 5 stars$10.65-4.7%$22.22+108.7%+176.5%$1.62B$53.61M-9.58240 Related Companies and Tools Related Companies IDEAYA Biosciences Alternatives Agios Pharmaceuticals Alternatives Schrödinger Alternatives Apogee Therapeutics Alternatives NewAmsterdam Pharma Alternatives Belite Bio Alternatives Travere Therapeutics Alternatives Disc Medicine Alternatives Iovance Biotherapeutics Alternatives Wave Life Sciences Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SNDL) was last updated on 2/17/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredTop Picks for Trump’s Pro-Crypto America10,000% Crypto Opportunities in 2025 27 of the brightest minds in crypto share exclusive intel… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SNDL Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SNDL With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.